At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Phase 2a Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of MEDI0382 Versus Placebo in Overweight/Obese Subjects With Type 2 Diabetes Mellitus Treated With Dapagliflozin and Metformin
In Brief
A Phase 2 clinical trial evaluating MEDI0382, Placebo, and 2 other interventions for Type 2 Diabetes Mellitus. Completed, enrolled 49 participants across 8 sites in 3 countries.
Detailed Summary
A Phase 2 study Comparing the effects on glucose control of MEDI0382 in combination with Dapagliflozin and Metformin compared to placebo in combination with Dapagliflozin and Metformin in overweight/obese participants with Type 2 Diabetes Mellitus (T2DM).
Study Details
Timeline
Interventions
Subcutaneous dose of MEDI0382 (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days).
Subcutaneous dose of placebo matched to MEDI0382.
Oral dose of dapaglifozin 10 mg tablet.
Oral dose of metformin tablet (maximum tolerated dose \[MTD\] \> 1 g).